Specific elimination of anti-DNA antibody-producing cells in systemic lupus erythematosus.
| Project/Area Number | 59870026 |
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
内科学一般
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
1984 – 1985
|
| Project Status |
Completed(Fiscal Year 1985)
|
| Budget Amount *help |
¥5,000,000 (Direct Cost : ¥5,000,000)
Fiscal Year 1985 : ¥1,100,000 (Direct Cost : ¥1,100,000)
Fiscal Year 1984 : ¥3,900,000 (Direct Cost : ¥3,900,000)
|
|---|
| Keywords | SLE / anti-DNA antibody / 抗イディオタイプ抗体 |
|---|
| Research Abstract |
The specific manipulation of anti-DNA antibody production is one of the prefered treatment of systemic lupus erythematosus (SLE). For this purpose, we induced DNE-specific tolerance in vitro using DNA-Dglutamic acid-D-lysine(DNA-D-GL).
The addition of the tolerogen reduced markedly the in vitro production of spontaneously occuring anti-ds and/or anti-ss DNA antibodies by SLE lymphocytes. The unresponsiveness was DNA-specific.
We also used monoclonal anti-idiotypic (Id) antibodies which were conjugated with neocarzinostatin (NCS), a cytotoxic agent. Human B cell clones, which produce anti-DNA autoantibodies, were killed by by in vitro treatment with anti-Id-NCS conjugates, while clones expressing an Id with irrelevant specificity were unaffected. Anti-Id-NCS also specifically suppressed anti-DNA autoantibodyproductin in vitro by human lymphocytes.
This approach will have a significant advantages in aborting clones, and will result in a potent therapeutic treatment for SLE.
|
Report
(1results)
Research Products
(10results)
